MRI for monitoring response to preventive treatment in multiple sclerosis

Expert Review of Neurotherapeutics

Volumn 9, Issue 3, 2009, Pages 305-307

  Pozzilli, Carlo ^a   Petsas, Nikolaos ^a   Prosperini, Luca ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; FUMARIC ACID; GADOLINIUM; GLATIRAMER; IMMUNOMODULATING AGENT; LAQUINIMOD; MITOXANTRONE; NATALIZUMAB; PLACEBO; TERIFLUNOMIDE;

CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG MECHANISM; EDITORIAL; HUMAN; IMMUNOTHERAPY; INCIDENCE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT IDENTIFICATION; PATIENT MONITORING; PROPHYLAXIS; TREATMENT RESPONSE; METHODOLOGY; MONITORING;

HUMANS; MAGNETIC RESONANCE IMAGING; MONITORING, PHYSIOLOGIC; MULTIPLE SCLEROSIS;

EID: 66449126558     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.9.3.305     Document Type: Editorial

References (28)

1. The IFN β Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFN β Multiple Sclerosis Study Group. Neurology 43, 655-661 (1993).
2. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-la for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39, 285-294 (1996).
3. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) study group. Randomised double-blind placebo-controlled study of interferon β-la in relapsing/remitting multiple sclerosis. Lancet 352, 1498-1504 (1998).
4. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45, 1268-1276 (1995).
5. Trojano M, Pellegrini F, Fuiani A et al. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann. Neurol. 61, 300-306 (2007).
6. Hartung HP, Gonsette R König N et al. Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360, 2018-2025 (2002).
7. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910 (2006).
8. Gasperini C, Ausili Cefaro L, Borriello G et al. Emerging oral drugs for multiple sclerosis. Expert Opin. Emerg. Drugs 13, 465-477 (2008).
9. Rio J, Nos C, Tintoré M et al. Defining the response to interferon β in relapsing-remitting multiple sclerosis patients. Ann. Neurol. 59, 344-352 (2006).
10. Shows that the proportion of patients defined as IFN-β responders changes according to predefined criteria of suboptimal response to therapy.
11. Portaccio E, Zipoli V, Siracusa G et al. Response to interferon-β therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. Mult. Scler. 12, 281-286 (2006).
12. Shows that the clinical characteristics able to predict clinical response change according to predefined criteria of suboptimal response to therapy.
13. Trojano M, Liguori M, Paolicelli D et al. Interferon β in relapsing-remitting multiple sclerosis: an independent post-marketing study in southern Italy. Mult. Scler. 9, 451-457 (2003).
14. Waubant E, Vukusic S, Gignoux L et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 61, 184-189 (2003).
15. O'Rourke K, Walsh C, Antonelli G et al. Predicting β-interferon failure in relapsing-remitting multiple sclerosis. Mult. Scler. 13, 336-342 (2007).
16. Koudriavtseva T, Pozzilli C, Fiorelli M et al. Determinants of Gd-enhanced MRI response to IFN β-1a treatment in relapsing-remitting multiple sclerosis. Mult. Scler. 4, 403-407 (1998).
17. Tomassini V, Paolillo A, Russo P et al. Predictors of long-term clinical response to interferon β therapy in relapsing multiple sclerosis. J. Neurol. 253, 287-293 (2006).
18. Rudick R Lee J, Simon J. Defining interferon β response status in multiple sclerosis patients. Ann. Neurol. 56, 548-555 (2004).
19. A post boc analysis showing that the occurrence of new MRI lesions during therapy correlates with a lack of response to IFN-β.
20. Durelli L, Berbero P, Bergui M et al. MRI activity and neutralizing antibody as predictor of response to IFNB treatment in MS. J. Neurol. Neurosurg. Psychiatry 79, 646-651 (2008).
21. Rio J, Rovira A, Tintoré M et al. Relationship between MRI lesion activity and response to IFN-β in relapsing-remitting multiple sclerosis patients. Mult. Scler. 14, 479-484 (2008).
22. Miller DH, Albert PS, Barkhof F et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann. Neurol. 39, 6-16 (1996).
23. Traboulsee A. MRI relapses have significant pathologic and clinical implications in multiple sclerosis. J. Neurol. Sci. 256, 19-22 (2007).
24. Yong VW. Differential mechanisms of action of interferon-β and glatiramer acetate in MS. Neurology 59, 802-808 (2002).
25. Barkhof F, Filippi M, Miller DH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120, 2059-2069 (1997).
26. Koudriavtseva T, Thompson AJ, Fiorelli M et al. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 62, 285-287 (1997).
27. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl. J. Med. 346, 158-64 (2002).
28. PRISMS (Prevention of Relapses and Disability by Interferon β-la Subcutaneously in Multiple Sclerosis) Study Group and UBC MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon β-la in relapsing MS. Neurology 56, 1628-36 (2001).